The latest price target for Milestone Pharmaceuticals (NASDAQ:MIST) was reported by HC Wainwright & Co. on October 14, 2024. The analyst firm set a price target for $25.00 expecting MIST to rise to within 12 months (a possible 1304.49% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Milestone Pharmaceuticals (NASDAQ:MIST) was provided by HC Wainwright & Co., and Milestone Pharmaceuticals reiterated their buy rating.

The last upgrade for Milestone Pharmaceuticals Inc happened on April 22, 2022 when Piper Sandler raised their price target to $10. Piper Sandler previously had a neutral for Milestone Pharmaceuticals Inc.

The last downgrade for Milestone Pharmaceuticals Inc happened on June 20, 2023 when Jefferies changed their price target from $8 to $4 for Milestone Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Milestone Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Milestone Pharmaceuticals was filed on October 14, 2024 so you should expect the next rating to be made available sometime around October 14, 2025.

While ratings are subjective and will change, the latest Milestone Pharmaceuticals (MIST) rating was a reiterated with a price target of $25.00 to $25.00. The current price Milestone Pharmaceuticals (MIST) is trading at is $1.78, which is out of the analyst’s predicted range.